Guangzhou, China - On September 28, 2022, Toumai^® Laparoscopic Surgery Robot (“Toumai^®”), independently developed by Shanghai MicroPort MedBot (Group) Co., Ltd. (“MicroPort^® MedBot^®”), successfully helped to complete the first radical treatment for left renal cancel with renal vein cancer assisted with a surgical robot, which was operated by the team of Director Lingwu Chen of Department of Urology from The First Affiliated Hospital of Sun Yat-sen University (“The First Affiliated Hospital”). Since the completion of installation in the middle of September, the MicroPort^® Toumai^® has helped to complete 12 challenging surgeries within half a month at  The First Affiliated Hospital. The stable performance demonstrated by the MicroPort^® Toumai^® in various complex and challenging surgeries in the Department of Urology has won the recognition and trust of experts. The successful completion of this surgery indicates that the Chinese-developed surgical robots have stepped into a new level in performing challenging clinical surgeries.

The surgery performed on September 28 was very challenging, which required the surgeon to separate the root of left renal vein down to the inferior vena cava. Since the root of left renal vein is very close to the aorta abdominalis and the inferior vena cava, any mis-operation may cause damage to the large vessels in these areas. So the surgery is very difficult, and may even threaten the life of the patient. The tissue surrounding the left renal vein suffered serious edema, and was surrounded by swollen lymph nodes. As a result, the venous return was blocked, the venae lumbales and the collateral circulation have visible dilation, which were susceptible to bleeding. The complex conditions had imposed extremely high requirements on the stability of robotic performance and the collaboration of the team.

During the surgery, the 3D image of high-resolution and high magnification provided by the MicroPort^® Toumai^® helped the surgeon achieve accurate anatomical positioning, and facilitated the surgeon assistant to perform real time suction and traction for exposure; the Surgeon Console is provided with mechanical simulation wrist, enabling full-coverage operation in the narrow anatomy space and helping the surgeon deal with complex lesions at ease; the 3D immersive image and hand shaking elimination functions of the MicroPort^® Toumai^® significantly improved the accuracy, convenience and safety of the surgery, and may help achieve “Accurate anatomy and fine resection”, thus providing a strong guarantee for safer and more minimally invasive surgery. The relentless pursuit for perfect surgical robot design is to provide the surgeons with the most real operation feeling and synchronous coordination among eyes, hands and the device, helping them deal with challenging and complex surgeries.

From installing the MicroPort^® Toumai^® on September 15 to September 29, the MicroPort^® Toumai^® has helped to complete 12 surgeries led by director Linghu Chen including 5 radical prostatectomy, 2 partial nephrectomy, 2 adrenalectomy, 1 retroperitoneal tumor resection, 1 radical treatment for left renal cancel with renal vein cancer and 1 nonfunctioning kidney nephrectomy.

The surgeons that participated in this clinical research projectwere able to quickly grasped the operation skills of the surgical robot after a short training by the MicroPort^® Toumai^® team. There are two reasons . Firstly, the stable performance of the MicroPort^® Toumai^® has significantly reduced the learning curve of the surgeons; secondly, the training team and the service support team of the MicroPort^® Toumai^® have provided them with customized professional session and systematic training, which ensured the professional operation by the surgeons and the stable performance of the robotic system, thus providing benefits for more patients.

Professor Lingwu Chen, the Director of the Department of Urology from The First Affiliated Hospital said: “The radical treatment for left renal cancel with renal vein cancer is one of the most complex and risky surgery in the field of urology surgeries. The successful application of MicroPort^® Toumai^® in The First Affiliated Hospital represents another remarkable progress of our hospital in the field of minimally invasive, advanced and accurate urinary surgeries. The good performance of MicroPort^® Toumai^® in the clinical application of urology surgery also means that our country has achieved breakthrough and world-leading level in the field of medical device manufacturing.”

Mr. Yu Liu, Executive Vice President and Chief Commercial Officer of MicroPort^® MedBot^®, said: The successful completion of the first radical treatment for left renal cancel with renal vein cancer assisted with the MicroPort^® Toumai^® in China will significantly prolong the life of the patient, improve the life quality, and bring more hope to the team of doctors and patients. The success of this surgery means the MicroPort^® Toumai^® has made new breakthroughs in the field of urinary surgeries, and accelerated the improvement of domestic robots in the clinical applications. In the future, we will continue to leverage the technology and development advantages of “Intelligent Manufacturing in China”, keep challenging more complex surgeries, bring benefits to more patients and ‘Make Surgery Easier, Safer and Less Invasive’.”